Literature DB >> 1702905

Application of two neutral MspI DNA polymorphisms in the analysis of hereditary protein C deficiency.

P H Reitsma1, W te Lintel Hekkert, E Koenhen, P A van der Velden, C F Allaart, P P Deutz-Terlouw, S R Poort, R M Bertina.   

Abstract

Screening of restriction enzyme digested DNA from normal and protein C deficient individuals with a variety of probes derived from the protein C locus has revealed the existence of two neutral MspI polymorphism. One polymorphism (MI), which is located approximately 7 kb upstream of the protein C gene, has allelic frequencies of 69 and 31%, and was used to exclude extensive gene deletions as a likely cause of type I protein C deficiency in 50% of cases in a panel of 22 families. Furthermore, the same polymorphism has been used in 5 doubly affected individuals establishing compound heterozygosity in 3 of these. The second, intragenic, polymorphism (MII) has allelic frequencies of 99 and 1% in the normal population. The frequency of the rare allele of this RFLP was with 7% much higher in a panel of 22 Dutch families with protein C deficiency. Interestingly, in all three probands that were heterozygous for MII the rare allele of MII coincided with a point mutation that leads to a stop codon in amino acid position 306 of the protein C coding sequence. This mutation may account for 14% of the protein C deficient individuals in The Netherlands.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702905

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  Exonic polymorphisms in the protein C gene: interethnic comparison between Caucasians and Asians.

Authors:  W Tsay; J S Greengard; J H Griffin
Journal:  Hum Genet       Date:  1994-08       Impact factor: 4.132

2.  Protein C deficiency and thromboembolism: recurrent mutation at Arg 306 in the protein C gene.

Authors:  C B Grundy; S Schulman; M Krawczak; J Kobosko; V V Kakkar; D N Cooper
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.